ArticleApplied biochemistry and biotechnology2022
Myrobalan-Mediated Nanocolloids in Controlling Marine Pathogens.
Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Green synthesis and characterization of Triphala SiODiscover nano · 2025Article
- Polyherbal nanoformulation: a potent antifungal agent on fungal pathogens of Coffea arabica.Discover nano · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Aquaculture production is affected by disease outbreak, which affects the production, profitability, and sustainability of the global aquaculture industry. Antibiotics have been widely used to control various infectious diseases. Indiscriminate usage of antibiotics results in development of antibiotic resistance in pathogens. This current study aims to synthesize myrobalan-mediated green silver nanocolloids (MBNc) by using the extract of three myrobalans and characterized by using various physiochemical techniques. Antibacterial potential of MBNc was screened in vibriosis causing pathogens (V. harveyi, V. alginolyticus, V. Parahaemolyticus), and foodborne pathogen S. haemolyticus, isolated from infected fish. Further, the presence of ESBL genes including CTX-M-15 and Amp C was analyzed in control and MBNc-treated strains. From our studies, it was observed that MBNc was very effective in controlling the growth. MBNc confirmed the anti-biofilm property in all tested marine pathogens and effectively abolish the genes encoding CTX-M-15 in tested pathogens. Thus, MBNc can be formulated to control the growth of marine pathogens and it can be used as an alternative to antibiotics to prevent infection in cage culturing and aquafarming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.